Neuracle has sold 13 brain implants at a listed RMB 475,000 each since July
Neuracle Technology (Shanghai) (博睿康), maker of China's first approved invasive brain-computer interface, has sold 13 NEO-ONE SCI implant systems and implanted 8 since its first commercial sale in July 2026, with more than 70 more in firm and intended orders. The system is listed at RMB 475,000 per set on procurement platforms in 27 provinces and is not covered by any basic medical insurance catalogue. Neuracle made the figures public on 29 September 2026 in its answers to the Shanghai Stock Exchange's first round of questions on its STAR Market listing application, 110 days after the application was accepted. First-half 2026 revenue was RMB 46.3 million, almost all from its non-invasive business and none from the implant, with a net loss of RMB 65.5 million. No listing committee meeting has been scheduled. None of the best-known Western developers of implanted BCIs, Neuralink, Synchron, Precision Neuroscience, Paradromics and Blackrock Neurotech, is publicly listed.